Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study
Lead Lantibiotic Clinical Candidate Selected from MU1140 Analog Pipeline TAMPA, Fla. & GERMANTOWN, Md.--(BUSINESS WIRE)--Jul. 28, 2015-- Oragenics, Inc. (NYSE MKT: OGEN) and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced today positive data on multiple compounds from Oragenics’ Mutacin 1140 (“MU1140”) lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate. The compounds were subjected to a standardized “proof of concept” animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomyc...
Intrexon Augments Management Team
- Jack Bobo named SVP, Chief Communications Officer - - Samuel Broder rejoins as SVP, Head of Health Sector - - Joel Liffmann appointed Senior Vice President, Finance - GERMANTOWN, Md., July 21, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance.  Mr. Bobo brings to Intrexon significant expertise in the analysis and communication of global trends in biotechnology, food and agriculture to audiences ...
Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Additional Positive Proof-of-Concept Data From in vivo Pre-Clinical Studies Highlighted EXTON, Pa. and GERMANTOWN, Md., July 20, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration for FCX-007, Fibrocell's lead orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). R...
Intrexon to Present at Upcoming Industrial Biotechnology Conferences
SOUTH SAN FRANCISCO, Calif., July 17, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Robert Walsh, Senior Vice President and Head of Intrexon's Energy Sector, will present at the following industrial biotechnology conferences: BIO World Congress on Industrial Biotechnology in The Importance of Feedstock and Product Strategy session, July 22, 2015, at 10:30 a.m. Eastern Time at the Palais des congres de Montreal in Montreal, Canada; GTL Technology Forum 2015 in The Future of Non FT GTL session, July 29, 2015, at 11:25 a.m. Central Time at the Norris Conference Center - City Center in Houston; and Jefferies 2015 I...
1